Astrazeneca Pharma India Limited - Due diligence report

A 360° intelligence report on Astrazeneca: trust score, financial health, credit view, compliance, directors, growth and distress signals - …

1979-07-11 Bangalore, Karnataka Active Listed Active Compliant
Share
AP Astrazeneca Pharma India Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Astrazeneca — 360° Intelligence Report

Generated from MCA filings & public records
73/100
Trust Score
Moderate

Astrazeneca is assessed as Moderate with a Trust Score of 73/100. Astrazeneca is an active public limited indian non-government company incorporated in 1979, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a high compliance risk and low financial risk profile.

Report generated on 16 Jul 2026 from the latest processed filings. Astrazeneca Pharma India Limited snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Weak

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreModerate
73/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreCaution Indicated
42/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
90/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
95/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
75/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
85/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
80/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 95/100 Low Risk
  • Liabilities ≈ 38% EBITDA - serviceable.
  • No open charges - unencumbered balance sheet.
  • Moderate gearing (D/E 1.42).
  • Profitable - internal accruals available.

Charges position: 0 open (-) · 1 satisfied (62.50 cr).

Banking relationships (from registered charges)
LenderChargesAmount
Il & Fs Trust Company Limited1 48.0 cr
Compliance Score: 42/100 Caution Indicated
  • Company status is Active as per MCA.
  • Annual filings current (balance sheet Mar 2025).
  • Flagged by authority: SEBI, BSE, BANKS.
  • Litigation present in 3 court forum(s).
  • Delayed payments to MSME suppliers disclosed (4 disclosure(s)).
  • 11 active GST registration(s).
Legal cases on record (3)
05

Director Intelligence

Stability score: 75/100
NameDIN / PANDesignationAppointedTenureDIN status
BHAVANA AGRAWAL 01234567 Director 01/04/2018 6 yrs Approved
REVATHY ASHOK 01234567 Director 01/04/2018 6 yrs Approved
Hooi Bien Chuah 01234567 Director 01/04/2018 6 yrs Approved
Bhavana Agrawal 01234567 Director 01/04/2018 6 yrs Approved
Sylvia Lorena Varela Ramon 01234567 Director 01/04/2018 6 yrs Approved
Jesus Javier Diaz Ropero Esteso 01234567 Director 01/04/2018 6 yrs Approved
MONICA WIDHANI 01234567 Director 01/04/2018 6 yrs Approved
SHILPA SHRIDHAR DIVEKAR 01234567 Director 01/04/2018 6 yrs Approved
Praveen Rao Akkinepally 01234567 Director 01/04/2018 6 yrs Approved
  • 9 directors on the board.
  • No disqualified or deactivated DINs.
  • 5 director exits in 3 years - high churn.
Director & KMP remuneration (FY 2023)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2025 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Astrazeneca Pharmaceuticals Ab
Subsidiaries
-
Group entities
-
Capital events
0 allotment(s) · 3 transfer(s)

Promoters hold a minority stake - exact percentages are part of the full report.

Group entityRelationship% held
Astrazeneca Pharmaceuticals Ab Holding Company 74.00%

Key managerial personnel: BHAVANA AGRAWAL (CFO) · Bhavana Agrawal (CFO) · Praveen Rao Akkinepally (Managing Director)

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 85 · Distress 80
Growth signals & trust indicators
Revenue acceleration: +2.1x over 4 year(s).
Latest year revenue grew 24%.
Asset base grew 0.86 - capacity expansion.
Operating for 47+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Outside liabilities up 61% in a year.
Compliance score is weak (42/100).
MSME payment delays disclosed - latest outstanding 9.04 Lakh.
3 court case(s) on record - see the legal section for details.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence63/100
Review suggested
Suitability as a supplier / customer counterparty.
  • Check the compliance flags before onboarding.
  • 1 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment80/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • No existing security registered - first-charge position available.
  • Compliance gaps should be priced into terms.
Investor view84/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 3 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
14 Aug 2025
Last AGM held
Annual general meeting
01 Jul 2025
Director appointed
Praveen Rao Akkinepally (Managing Director)
31 Mar 2025
Latest balance sheet
Filed with ROC
21 Dec 2024
Director ceased
Jesus Javier Diaz Ropero Esteso
Director ceased
MONICA WIDHANI
13 Nov 2024
Director appointed
Jesus Javier Diaz Ropero Esteso (Director)
25 Sep 2024
Director appointed
MONICA WIDHANI (Director)
15 Mar 2024
Director appointed
BHAVANA AGRAWAL (CFO)
08 Feb 2024
Director ceased
Bhavana Agrawal
05 Feb 2024
Director ceased
Hooi Bien Chuah
Director ceased
Sylvia Lorena Varela Ramon
21 Dec 2023
Director appointed
Sylvia Lorena Varela Ramon (Director)
09 Nov 2023
Director appointed
Hooi Bien Chuah (Director)
01 Oct 2023
Director appointed
Bhavana Agrawal (CFO)
01 Jan 2023
Director ceased
SANJEEV KUMAR PANCHAL
10

Key Observations

Auto-generated from the data above
Revenue grew 38% over the last 4 financial year(s).
Net profit margin moved from 1.42 to 2.1x.
Debt-to-equity stands at 24% - manageable leverage.
Net worth is positive.
9 active director(s) / partner(s); board looks stable and experienced.
11 active GST registration(s) indicate ongoing business operations.
All 1 registered charge(s) stand satisfied - past borrowings repaid.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a minority stake as per the FY 2025 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Leefordcosmacia U24230PB2006PLC029786 Ludhiana, Punjab, India
Bodal L24110GJ1986PLC009003 Daskroi, Gujarat, India
Navin Fluorine L24110MH1998PLC115499 Mumbai, Maharashtra, India
Rubamin U24299GJ1987PTC009942 Vadodara, Gujarat, India
Tgv Sraac L24110AP1981PLC003077 Kurnool, Andhra Pradesh, India
Sigmachemicals U02411KA2003PTC031488 Bangalore, Karnataka, India
Vidyaherbs U24233KA2004PTC033937 Bengaluru, Karnataka, India
Tamilnadu Petroproducts L23200TN1984PLC010931 Chennai, Tamil Nadu, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Astrazeneca before audits and certifications: compliance score 42/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Astrazeneca: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Favourable lending indicators. Credit risk score 95/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 85/100, margin trends, ownership structure and peer set for Astrazeneca - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Review suggested. Trust score 73/100, distress signals and MSME payment-delay disclosures - know whether Astrazeneca pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (3 case(s) on record), regulatory flags, charge documents trail and director networks for Astrazeneca - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Astrazeneca an active company?

Astrazeneca has MCA status “Active” with a compliance score of 42/100 (Caution Indicated).

Is Astrazeneca financially healthy?

Astrazeneca has a Financial Health Score of 90/100 (Low Risk) based on its filed financial statements.

Should I do business with Astrazeneca?

Its overall Trust Score is 73/100 (Moderate). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Astrazeneca?

The ultimate holding entity is Astrazeneca Pharmaceuticals Ab. 9 active director(s) are on record.

Does Astrazeneca have loans or charges against its assets?

No open charges - all 1 registered charge(s) stand satisfied, indicating past borrowings were repaid.

Is Astrazeneca up to date with its ROC filings?

Annual filings current (balance sheet Mar 2025). Overall compliance score: 42/100 (Caution Indicated).

Is it risky to lend to Astrazeneca?

Its Credit Risk Score is 95/100 (Low Risk). Banker verdict: Favourable lending indicators.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.